nitric oxide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1948 10102-43-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nitric oxide
  • nitrogen oxide
  • nitrogen monoxide
  • INOmax
A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. It has been shown to have in vitro activity against severe acute res-piratory syndrome corona-virus (SARS-CoV-1) but evidence supporting the use of inhaled nitric oxide in COVID-19 patients is currently limited.
  • Molecular weight: 30.01
  • Formula: NO
  • CLOGP:
  • LIPINSKI: None
  • HAC: 2
  • HDO: 0
  • TPSA: 34.14
  • ALOGS:
  • ROTB: 0

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Dec. 23, 1999 FDA INO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intraventricular haemorrhage neonatal 125.82 53.06 17 1127 140 46684778
Oxygen saturation decreased 111.77 53.06 47 1097 69117 46615801
Device failure 83.68 53.06 21 1123 5938 46678980
Patent ductus arteriosus 76.70 53.06 18 1126 3844 46681074
Pulmonary hypertension 53.10 53.06 23 1121 35970 46648948

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Oxygen saturation decreased 109.88 61.93 46 1085 43394 29907953
Neonatal disorder 76.06 61.93 15 1116 911 29950436
Hypertrophic cardiomyopathy 69.91 61.93 14 1117 919 29950428
Pulmonary hypertension 68.30 61.93 26 1105 19010 29932337
Pulmonary haemorrhage 65.25 61.93 21 1110 9371 29941976
Product use issue 63.37 61.93 32 1099 45984 29905363

Pharmacologic Action:

SourceCodeDescription
ATC R07AX01 RESPIRATORY SYSTEM
OTHER RESPIRATORY SYSTEM PRODUCTS
OTHER RESPIRATORY SYSTEM PRODUCTS
Other respiratory system products
FDA PE N0000009909 Vasodilation
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D000975 Antioxidants
MeSH PA D001993 Bronchodilator Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D045462 Endothelium-Dependent Relaxing Factors
MeSH PA D016166 Free Radical Scavengers
MeSH PA D064426 Gasotransmitters
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D019141 Respiratory System Agents
MeSH PA D014665 Vasodilator Agents
CHEBI has role CHEBI:25512 neurotransmitters
CHEBI has role CHEBI:35523 bronchodilator agents
CHEBI has role CHEBI:35620 vasodilator
CHEBI has role CHEBI:48578 free-radical scavenger
CHEBI has role CHEBI:62488 signaling molecules
CHEBI has role CHEBI:75771 mus musculus metabolite
CHEBI has role CHEBI:76971 e.coli metabolites
CHEBI has role CHEBI:77746 h. sapiens metabolites
FDA EPC N0000175940 Vasodilator

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Pulmonary hypertension indication 70995007 DOID:6432
Persistent pulmonary hypertension of the newborn indication 233815004 DOID:13042
Methemoglobinemia contraindication 38959009 DOID:10783
Left heart failure contraindication 85232009
Congenital Heart Defect Requiring Open Patent Ductus Arteriosus contraindication

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Soluble guanylate cyclase Enzyme ACTIVATOR CHEMBL CHEMBL

External reference:

IDSource
4021248 VUID
N0000148689 NUI
D00074 KEGG_DRUG
4021248 VANDF
C1330345 UMLSCUI
CHEBI:16480 CHEBI
NO PDB_CHEM_ID
CHEMBL1200689 ChEMBL_ID
CHEMBL1234579 ChEMBL_ID
D009569 MESH_DESCRIPTOR_UI
DB00435 DRUGBANK_ID
31C4KY9ESH UNII
145068 PUBCHEM_CID
405139 RXNORM
17479 MMSL
47106 MMSL
d04508 MMSL
012088 NDDF
409378005 SNOMEDCT_US
6710000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Noxivent 101 HUMAN PRESCRIPTION DRUG LABEL 1 59579-101 GAS 100 mg RESPIRATORY (INHALATION) ANDA 16 sections
Noxivent 102 HUMAN PRESCRIPTION DRUG LABEL 1 59579-102 GAS 800 mg RESPIRATORY (INHALATION) ANDA 16 sections
INOmax HUMAN PRESCRIPTION DRUG LABEL 1 64693-002 GAS 0.98 mg RESPIRATORY (INHALATION) NDA 23 sections
INOmax HUMAN PRESCRIPTION DRUG LABEL 1 64693-002 GAS 0.98 mg RESPIRATORY (INHALATION) NDA 23 sections
Nitric Oxide Nitrogen Mix HUMAN PRESCRIPTION DRUG LABEL 2 67989-011 GAS 5 mL RESPIRATORY (INHALATION) unapproved medical gas 1 sections
GENOSYL HUMAN PRESCRIPTION DRUG LABEL 1 72385-001 GAS 0.98 mg RESPIRATORY (INHALATION) NDA 23 sections
NOW st HUMAN OTC DRUG LABEL 1 80519-301 LIQUID 1.12 g TOPICAL unapproved drug other 12 sections